为什么以及如何模拟平台试验?向EU-PEARL学习。

IF 3.9 3区 医学 Q1 HEALTH CARE SCIENCES & SERVICES BMC Medical Research Methodology Pub Date : 2025-01-17 DOI:10.1186/s12874-024-02453-6
Elias Laurin Meyer, Tobias Mielke, Marta Bofill Roig, Michaela Maria Freitag, Peter Jacko, Pavla Krotka, Peter Mesenbrink, Tom Parke, Sonja Zehetmayer, Dario Zocholl, Franz König
{"title":"为什么以及如何模拟平台试验?向EU-PEARL学习。","authors":"Elias Laurin Meyer, Tobias Mielke, Marta Bofill Roig, Michaela Maria Freitag, Peter Jacko, Pavla Krotka, Peter Mesenbrink, Tom Parke, Sonja Zehetmayer, Dario Zocholl, Franz König","doi":"10.1186/s12874-024-02453-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Platform trials are innovative clinical trials governed by a master protocol that allows for the evaluation of multiple investigational treatments that enter and leave the trial over time. Interest in platform trials has been steadily increasing over the last decade. Due to their highly adaptive nature, platform trials provide sufficient flexibility to customize important trial design aspects to the requirements of both the specific disease under investigation and the different stakeholders. The flexibility of platform trials, however, comes with complexities when designing such trials. In the past, we reviewed existing software for simulating clinical trials and found that none of them were suitable for simulating platform trials as they do not accommodate the design features and flexibility inherent to platform trials, such as staggered entry of treatments over time.</p><p><strong>Results: </strong>We argued that simulation studies are crucial for the design of efficient platform trials. We developed and proposed an iterative, simulation-guided \"vanilla and sprinkles\" framework, i.e. from a basic to a more complex design, for designing platform trials. We addressed the functionality limitations of existing software as well as the unavailability of the coding therein by developing a suite of open-source software to use in simulating platform trials based on the R programming language. To give some examples, the newly developed software supports simulating staggered entry of treatments throughout the trial, choosing different options for control data sharing, specifying different platform stopping rules and platform-level operating characteristics. The software we developed is available through open-source licensing to enable users to access and modify the code. The separate use of two of these software packages to implement the same platform design by independent teams obtained the same results.</p><p><strong>Conclusion: </strong>We provide a framework, as well as open-source software for the design and simulation of platform trials. The software tools provide the flexibility necessary to capture the complexity of platform trials.</p>","PeriodicalId":9114,"journal":{"name":"BMC Medical Research Methodology","volume":"25 1","pages":"12"},"PeriodicalIF":3.9000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740366/pdf/","citationCount":"0","resultStr":"{\"title\":\"Why and how should we simulate platform trials? Learnings from EU-PEARL.\",\"authors\":\"Elias Laurin Meyer, Tobias Mielke, Marta Bofill Roig, Michaela Maria Freitag, Peter Jacko, Pavla Krotka, Peter Mesenbrink, Tom Parke, Sonja Zehetmayer, Dario Zocholl, Franz König\",\"doi\":\"10.1186/s12874-024-02453-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Platform trials are innovative clinical trials governed by a master protocol that allows for the evaluation of multiple investigational treatments that enter and leave the trial over time. Interest in platform trials has been steadily increasing over the last decade. Due to their highly adaptive nature, platform trials provide sufficient flexibility to customize important trial design aspects to the requirements of both the specific disease under investigation and the different stakeholders. The flexibility of platform trials, however, comes with complexities when designing such trials. In the past, we reviewed existing software for simulating clinical trials and found that none of them were suitable for simulating platform trials as they do not accommodate the design features and flexibility inherent to platform trials, such as staggered entry of treatments over time.</p><p><strong>Results: </strong>We argued that simulation studies are crucial for the design of efficient platform trials. We developed and proposed an iterative, simulation-guided \\\"vanilla and sprinkles\\\" framework, i.e. from a basic to a more complex design, for designing platform trials. We addressed the functionality limitations of existing software as well as the unavailability of the coding therein by developing a suite of open-source software to use in simulating platform trials based on the R programming language. To give some examples, the newly developed software supports simulating staggered entry of treatments throughout the trial, choosing different options for control data sharing, specifying different platform stopping rules and platform-level operating characteristics. The software we developed is available through open-source licensing to enable users to access and modify the code. The separate use of two of these software packages to implement the same platform design by independent teams obtained the same results.</p><p><strong>Conclusion: </strong>We provide a framework, as well as open-source software for the design and simulation of platform trials. The software tools provide the flexibility necessary to capture the complexity of platform trials.</p>\",\"PeriodicalId\":9114,\"journal\":{\"name\":\"BMC Medical Research Methodology\",\"volume\":\"25 1\",\"pages\":\"12\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740366/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Medical Research Methodology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12874-024-02453-6\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medical Research Methodology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12874-024-02453-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景:平台试验是由一个主方案管理的创新临床试验,该方案允许随着时间的推移对进入和退出试验的多种研究性治疗进行评估。在过去的十年里,人们对平台试验的兴趣一直在稳步增长。由于其高度适应性,平台试验提供了足够的灵活性,可以根据所调查的特定疾病和不同利益相关者的要求定制重要的试验设计方面。然而,在设计此类试验时,平台试验的灵活性带来了复杂性。过去,我们回顾了现有的模拟临床试验的软件,发现它们都不适合模拟平台试验,因为它们不适应平台试验固有的设计特征和灵活性,例如随着时间的推移交错进入治疗。结果:我们认为模拟研究对于设计有效的平台试验至关重要。我们开发并提出了一个迭代的、以模拟为指导的“香草和撒糖”框架,即从基本设计到更复杂的设计,用于设计平台试验。我们通过开发一套开源软件来模拟基于R编程语言的平台试验,解决了现有软件的功能限制以及其中编码的不可用性。举例来说,新开发的软件支持在整个试验过程中模拟交错进入治疗方案,选择不同的控制数据共享选项,指定不同的平台停止规则和平台级操作特性。我们开发的软件可以通过开源许可获得,用户可以访问和修改代码。由独立的团队分别使用这两个软件包来实现相同的平台设计,得到了相同的结果。结论:我们为平台试验的设计和仿真提供了一个框架和开源软件。软件工具提供了捕捉平台试验复杂性所需的灵活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Why and how should we simulate platform trials? Learnings from EU-PEARL.

Background: Platform trials are innovative clinical trials governed by a master protocol that allows for the evaluation of multiple investigational treatments that enter and leave the trial over time. Interest in platform trials has been steadily increasing over the last decade. Due to their highly adaptive nature, platform trials provide sufficient flexibility to customize important trial design aspects to the requirements of both the specific disease under investigation and the different stakeholders. The flexibility of platform trials, however, comes with complexities when designing such trials. In the past, we reviewed existing software for simulating clinical trials and found that none of them were suitable for simulating platform trials as they do not accommodate the design features and flexibility inherent to platform trials, such as staggered entry of treatments over time.

Results: We argued that simulation studies are crucial for the design of efficient platform trials. We developed and proposed an iterative, simulation-guided "vanilla and sprinkles" framework, i.e. from a basic to a more complex design, for designing platform trials. We addressed the functionality limitations of existing software as well as the unavailability of the coding therein by developing a suite of open-source software to use in simulating platform trials based on the R programming language. To give some examples, the newly developed software supports simulating staggered entry of treatments throughout the trial, choosing different options for control data sharing, specifying different platform stopping rules and platform-level operating characteristics. The software we developed is available through open-source licensing to enable users to access and modify the code. The separate use of two of these software packages to implement the same platform design by independent teams obtained the same results.

Conclusion: We provide a framework, as well as open-source software for the design and simulation of platform trials. The software tools provide the flexibility necessary to capture the complexity of platform trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Medical Research Methodology
BMC Medical Research Methodology 医学-卫生保健
CiteScore
6.50
自引率
2.50%
发文量
298
审稿时长
3-8 weeks
期刊介绍: BMC Medical Research Methodology is an open access journal publishing original peer-reviewed research articles in methodological approaches to healthcare research. Articles on the methodology of epidemiological research, clinical trials and meta-analysis/systematic review are particularly encouraged, as are empirical studies of the associations between choice of methodology and study outcomes. BMC Medical Research Methodology does not aim to publish articles describing scientific methods or techniques: these should be directed to the BMC journal covering the relevant biomedical subject area.
期刊最新文献
A generative model for evaluating missing data methods in large epidemiological cohorts. Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications. Multiple states clustering analysis (MSCA), an unsupervised approach to multiple time-to-event electronic health records applied to multimorbidity associated with myocardial infarction. Matching plus regression adjustment for the estimation of the average treatment effect on survival outcomes: a case study with mosunetuzumab in relapsed/refractory follicular lymphoma. Protocol publication rate and comparison between article, registry and protocol in RCTs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1